clinical trial · NCT05288166
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
Eli Lilly and Company·phase3·active not recruiting·n = 925
Prostatic NeoplasmsNeoplasm MetastasisUrogenital NeoplasmsPhysiological Effects of DrugsAntineoplastic AgentsAntineoplastic Agents, HormonalAndrogensHormonesAbemaciclibAbirateronePrednisone or PrednisolonePlacebo for Abemaciclib
brief summary
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
started
Apr 14, 2022
primary completion
Feb 15, 2024
completion
Oct 1, 2027
last updated
Jul 1, 2026
official title
CYCLONE 3: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Abemaciclib in Combination With Abiraterone Plus Prednisone in Men With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol